Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Twice-Yearly Subcutaneous Lenacapavir and Daily Oral PrEP for HIV-1 Prevention
2023-001024-42Phase 3
- Sponsor
- Gilead Sciences
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lenacapavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Gilead Sciences.
02
Drugs
lenacapavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2023-001024-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-001024-42.